BLOG

endpoints

Partnered with Gilead and Sanofi, protein degradation specialist Nurix bags $120M to chart its own clinical path

On the same day that Cambridge, MA-based Kymera Therapeutics unveiled a $102 million round to enter into development phase, Nurix said it has raised $120 million to do the same out of San Francisco’s Mission Bay.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}